Biogen (BIIB) PT Raised to $300 at Cantor Fitzgerald on 30% Aducanumab POS
Tweet Send to a Friend
Cantor Fitzgerald analyst Alethia Young raised the price target on Biogen (NASDAQ: BIIB) to $300.00 (from $250.00) to reflect a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
